Tianda Pharmaceuticals Limited (HKG:0455)

Tianda Pharmaceuticals Balance Sheet

Financials in millions HKD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	85.69	162.44	340.28	334	234.98
Short-Term Investments	6.14	8.43	21.73	3.31	2.97
Trading Asset Securities	-	-	3.17	14.58	-
Cash & Short-Term Investments	91.83	170.87	365.17	351.9	237.96
Cash Growth	-46.26%	-53.21%	3.77%	47.88%	-24.05%
Accounts Receivable	77.42	104.8	138.75	141.74	145.21
Other Receivables	3.97	1.57	4.07	3.15	2.93
Receivables	81.39	106.38	142.82	144.89	148.14
Inventory	40.21	65.15	48.19	74.89	64.39
Prepaid Expenses	2.45	1.81	1.99	5.76	8.14
Other Current Assets	-	-	-	-	147.77
Total Current Assets	215.88	344.21	558.17	577.45	606.41
Property, Plant & Equipment	386.09	412.74	400.51	433.09	377.78
Long-Term Investments	-	9.22	0.74	1.77	6.87
Goodwill	90.39	95.23	95.95	106.21	103.27
Other Intangible Assets	27.21	1.31	1.75	15.51	19.56
Long-Term Deferred Charges	33.32	19.36	4.37	6.43	8.23
Other Long-Term Assets	12.14	35.22	26.97	23.7	11.35
Total Assets	765.02	917.29	1,088	1,164	1,133
Accounts Payable	77.82	117.99	80.73	110.11	91.54
Accrued Expenses	29.37	64.31	71.19	63.99	59.9
Current Portion of Long-Term Debt	122.07	96.49	64.67	57.26	18.89
Current Portion of Leases	2.19	5.68	5.63	4.6	4.18
Current Income Taxes Payable	0.75	3.74	3.72	4.24	3.73
Current Unearned Revenue	8.43	13.71	111.73	14.08	11.76
Other Current Liabilities	10.36	11.38	24.76	17.37	24.23
Total Current Liabilities	251	313.31	362.43	271.66	214.23
Long-Term Debt	-	8.36	61.97	90.63	110.8
Long-Term Leases	3.18	3.07	8.77	7.94	11.65
Long-Term Unearned Revenue	-	-	0.09	0.19	0.3
Long-Term Deferred Tax Liabilities	5.18	0.61	0.96	4.65	5.97
Total Liabilities	259.36	325.35	434.23	375.08	342.97
Common Stock	215	215	215	215	215
Additional Paid-In Capital	359.07	364.66	364.66	364.66	364.66
Retained Earnings	37.05	98.42	128.17	186.77	212.13
Comprehensive Income & Other	-105.29	-86.02	-80	-9.68	-35.09
Total Common Equity	505.84	592.07	627.83	756.75	756.71
Minority Interest	-0.17	-0.13	26.41	32.32	33.79
Shareholders' Equity	505.67	591.94	654.24	789.08	790.49
Total Liabilities & Equity	765.02	917.29	1,088	1,164	1,133
Total Debt	127.45	113.6	141.05	160.43	145.53
Net Cash (Debt)	-35.61	57.28	224.12	191.47	92.43
Net Cash Growth	-	-74.44%	17.06%	107.15%	-67.92%
Net Cash Per Share	-0.02	0.03	0.10	0.09	0.04
Filing Date Shares Outstanding	2,150	2,150	2,150	2,150	2,150
Total Common Shares Outstanding	2,150	2,150	2,150	2,150	2,150
Working Capital	-35.12	30.9	195.75	305.79	392.18
Book Value Per Share	0.24	0.28	0.29	0.35	0.35
Tangible Book Value	388.24	495.53	530.13	635.03	633.88
Tangible Book Value Per Share	0.18	0.23	0.25	0.30	0.29
Buildings	242.08	228.71	229.42	249.16	32.18
Machinery	214.64	212.46	179.2	184.23	87.97
Construction In Progress	25.34	40.39	28.98	23.69	267.05
Leasehold Improvements	5.72	4.71	4.02	4.17	3.88

Updated Sep 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.